« Return to News | R&D Trends | Drug Sponsors

Thrasos secures $35M for THR-184 phase II program for acute kidney injury

Friday, October 26, 2012 11:39 AM

Thrasos Therapeutics, a Canadian clinical stage biotherapeutics company, has completed a $35 million financing for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI).

The round was led by new investor, SR One, with funds coming from the GSK Canada Life Sciences Innovation Fund, part of GlaxoSmithKline's commitment to advance the development and commercialization of scientific innovation in Canada. Five additional new investors and existing investor, SW Co, joined in the round. The new investors were Advanced Technology Ventures (ATV), Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures.

With the financing, Thrasos plans to advance THR-184 through phase II clinical proof of concept in AKI.

"Thrasos' lead therapeutic program for acute kidney injury has demonstrated strong potential in preliminary studies and we are pleased to support this program and other potential opportunities in renal disease, a field of huge unmet medical need,” said Dr. Jens Eckstein, president of SR One and lead investor of the financing.

Richard Andrews, president and CEO of Thrasos, said, "AKI represents an important market opportunity in North America and is a daunting challenge with no current treatment available. We are encouraged by the positive data achieved in our preclinical and phase I studies with THR-184 and look forward to advancing this program into phase II and ultimately having a positive impact on patients with the condition."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.